An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11912-023-01389-2.pdf
Reference73 articles.
1. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17(9):1738–52. https://doi.org/10.1038/sj.leu.2403099.
2. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the Juxtamembrane domain. Mol Cell. 2004;13(2):169–78. https://doi.org/10.1016/S1097-2765(03)00505-7.
3. Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–92. https://doi.org/10.1182/blood-2009-03-209999.
4. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114(24):5034–43. https://doi.org/10.1182/blood-2008-12-196055.
5. Mead AJ, Kharazi S, Atkinson D, et al. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors. Cell Rep. 2013;3(6):1766–76. https://doi.org/10.1016/j.celrep.2013.04.031.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting the bone marrow niche, moving towards leukemia eradication;Frontiers in Hematology;2024-07-22
2. Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies;ACS Pharmacology & Translational Science;2024-07-02
3. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada;Transplantation and Cellular Therapy;2024-07
4. PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives;MedComm;2024-06
5. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3